Novorapid Pumpcart (Insulin Aspart)

Insulin aspart, the active ingredient in Novorapid Pumpcart, is a rapid‑acting insulin analog presented as a cartridge for subcutaneous infusion via insulin pumps. It provides fast‑acting glucose control for people with type 1 and type 2 diabetes mellitus, mimicking physiological insulin secretion after meals.

GNH USA supplies Novorapid Pumpcart as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions.

Insulin aspart is a rapid‑acting insulin analog used to manage hyperglycaemia in diabetes mellitus. - Type 1 Diabetes: provides mealtime glucose control to match carbohydrate intake. - Type 2 Diabetes: improves postprandial blood‑glucose levels when combined with basal insulin or oral agents. - Insulin Pump Therapy: delivers continuous subcutaneous insulin for precise dosing. - Gestational Diabetes: helps achieve target postprandial glucose when diet alone is insufficient.

Common Side Effects: - Hypoglycaemia: low blood‑glucose episodes, especially if meals are missed. - Injection site reactions: redness, swelling or itching at the infusion site. - Lipodystrophy: localized fat tissue changes with repeated use. - Weight gain: modest increase associated with improved glycaemic control. - Local allergic reaction: mild rash or urticaria at the site.

Serious or Rare Side Effects: - Severe hypoglycaemia: neurological impairment requiring assistance. - Anaphylaxis: systemic allergic reaction with airway compromise. - Hypokalemia: low serum potassium levels. - Insulin antibodies: may alter insulin action. - Edema: fluid retention, particularly in the lower extremities. - Urticaria: widespread hives indicating hypersensitivity.

Before using Novorapid Pumpcart, consider the following precautions: - Hypoglycaemia risk: monitor blood glucose frequently and adjust carbohydrate intake. - Renal impairment: evaluate dose requirements as clearance may be reduced. - Pregnancy and lactation: use only if the expected benefit outweighs potential risk. - Alcohol consumption: may potentiate hypoglycaemia; advise moderation. - Concomitant medications: review all drugs for possible interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin aspart may interact with several medicines that affect glucose levels.

Major Interactions (Avoid): - Beta‑blockers: can mask hypoglycaemia symptoms, making detection difficult. - MAO inhibitors: may potentiate insulin’s glucose‑lowering effect, increasing hypoglycaemia risk. - Sulfonylureas or other oral hypoglycaemic agents: combined use can cause severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, requiring dose adjustment. - Thiazide diuretics: can raise blood glucose, potentially reducing insulin efficacy. - Corticosteroids: may increase insulin requirements due to hyperglycaemic effect.